急性髓系白血病CAR-T治疗的靶点选择  

Target Selection of CAR-T Therapy in Acute Myeloid Leukemia——Review

作　　者：邵若男 辛红蕾 施小凤 SHAO Ruo-Nan;XIN Hong-Lei;SHI Xiao-Feng(Department of Hematology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing 212100,Jiangsu Province,China)

机构地区：[1]南京医科大学第二附属医院血液科,江苏南京212100

出　　处：《中国实验血液学杂志》2024年第3期965-969,共5页Journal of Experimental Hematology

基　　金：国家自然科学基金(81700130)。

摘　　要：嵌合抗原受体(CAR)T细胞疗法将抗原抗体的靶向识别与T细胞的杀伤作用相结合,已成为最有应用前景的肿瘤治疗方法之一。在淋巴系肿瘤中,CAR-T显示出了强大的治疗效果,并已陆续在临床中得到应用。然而,在急性髓系白血病的治疗中尚未发现如淋巴系肿瘤中CD19一样有效且特异的靶点,因此,尝试多种靶点,并且使用优化策略,以增强疗效、减轻毒性,是目前主要的研究方向。本文介绍了近年来CAR-T治疗急性髓系白血病靶点的最新研究进展,分析了目前亟待解决的相关问题,并总结了研究中提到的优化构建策略,希望能为相关研究的进行以及产品的临床应用提供参考。Chimeric antigen receptor(CAR)T cell therapy,one of the most promising tumor treatments,combines the targeted recognition of antigen and antibody with the killing effect of T cells.CAR-T has shown a strong therapeutic effect in lymphoid tumors and been applied in clinical practice.However,in the treatment of acute myeloid leukemia(AML),no effective and specific target like CD19 in lymphoid tumors has been found.Therefore,the key research direction is to try multiple probabilities and use optimization strategies to enhance efficacy and reduce toxicity.This review introduces the latest research progress of AML targets in CAR-T therapy in recent years,analyzes the related problems that need to be solved at present,and summarizes the optimization construction strategies mentioned in the research.Hope it can provide reference for related research and clinical application of related product.

关 键 词：急性髓系白血病 嵌合抗原受体T细胞 靶向治疗 

分 类 号：R733.71[医药卫生—肿瘤]